16 results on '"Bilici, Ahmet"'
Search Results
2. Integrated FDG-PET/CT contribution over cross-sectional imaging in recurrence or progression of pancreaticobiliary neoplasms.
- Author
-
Karaalioglu B, Cakir T, Kutlu Y, Seker M, and Bilici A
- Subjects
- Humans, Retrospective Studies, Sensitivity and Specificity, Neoplasm Recurrence, Local diagnostic imaging, Positron-Emission Tomography, Magnetic Resonance Imaging methods, Radiopharmaceuticals, Positron Emission Tomography Computed Tomography methods, Fluorodeoxyglucose F18
- Abstract
Purpose: We aim to compare FDG-PET/CT and cross-sectional imaging (contrastenhanced CT/MRI) diagnostic abilities in detecting recurrence/progression of pancreaticobiliary system tumors and to reveal the clinical impact of integrated FDGPET/CT to CT/MRI on patient management., Materials and Methods: FDG-PET/CT and CT/MRI scans of 70 patients from initiation of treatment until proven recurrence/progression were retrospectively evaluated. FDGPET/CT and contrast-enhanced CT/MRI accuracy, sensitivity, specificity, PPV and NPV are compared in terms of overall recurrence/progression diagnosis and sitespecific concern; local disease, local lymph node, and distant organ metastasis. The impact of integrated FDG-PET/CT on patient management is scrutinized., Results: CT/MRI has higher sensitivity than FDG-PET/CT in detecting loco-regional involvement (90% vs 76.7% P: 0.152), local lymph node metastasis (88.9% vs 77.8%, P: 0.380) and distant organ metastasis (96.5% vs 80.7%; P: 0.006) in tumor recurrence/progression. In overall diagnosis, CT/MRI is more sensitive and accurate but less specific than FDG-PET/CT (92.3% vs 87.7%; 87.1% vs 84.2%; 40% vs 20%, respectively). In 8% (6/70) of patients FDG-PET/CT had a major impact on patient management., Conclusion: FDG-PET/CT and cross-sectional imaging have different advantages and shortcomings. In recurrence/progression, recognition of early changes is more feasible by CT/MRI. However, inconsistency of morphologic and metabolic findings is important reason of cross-sectional imaging failure. FDG-PET/CT is superior in showing extraabdominal metastases, but missing small-volume lesions and misinterpreting inflammatory changes are still a problem lowering its sensitivity. Nevertheless FDGPET/CT is good option for guiding undetermined imaging findings or clinic-radiologic mismatch., (© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
3. The Effect of Primary Surgery in Patients with De Novo Stage IV Breast Cancer with Bone Metastasis Only (Protocol BOMET MF 14-01): A Multi-Center, Prospective Registry Study.
- Author
-
Soran A, Dogan L, Isik A, Ozbas S, Trabulus DC, Demirci U, Karanlik H, Soyder A, Dag A, Bilici A, Dogan M, Koksal H, Sendur MAN, Gulcelik MA, Maralcan G, Cabioglu N, Yeniay L, Utkan Z, Simsek T, Karadurmus N, Daglar G, Yildiz B, Uras C, Tukenmez M, Yildirim A, Kutun S, Ozaslan C, Karaman N, Akcay MN, Toktas O, and Sezgin E
- Subjects
- Female, Humans, Mastectomy, Multicenter Studies as Topic, Neoplasm Metastasis, Neoplasm Recurrence, Local surgery, Registries, Retrospective Studies, Survival Rate, Breast Neoplasms surgery
- Abstract
Background: More evidence shows that primary surgery for de novo metastatic breast cancer (BC) prolongs overall survival (OS) in selected cases. The aim of this study was to evaluate the role of locoregional treatment (LRT) in BC patients with de novo stage IV bone only metastasis (BOM)., Methods: The prospective, multicenter registry study BOMET MF14-01 was initiated in May 2014. Patients with de novo stage IV BOM BC were divided into two groups: those receiving systemic treatment (ST group) and those receiving LRT (LRT group). Patients who received LRT were further divided into two groups: ST after LRT (LRT + ST group) and ST before LRT (ST + LRT group)., Results: We included 505 patients in this study; 240 (47.5%) patients in the ST group and 265 (52.5%) in the LRT group. One hundred and thirteen patients (26.3%) died in the 34-month median follow-up, 85 (35.4%) in the ST group and 28 (10.5%) in LRT group. Local progression was observed in 39 (16.2%) of the patients in the ST group and 18 (6.7%) in the LRT group (p = 0.001). Hazard of death was 60% lower in the LRT group compared with the ST group (HR 0.40, 95% CI 0.30-0.54, p < 0.0001)., Conclusion: In this prospectively maintained registry study, we found that LRT prolonged survival and decreased locoregional recurrence in the median 3-year follow-up. Timing of primary breast surgery either at diagnosis or after ST provided a survival benefit similar to ST alone in de novo stage IV BOM BC patients., (© 2021. Society of Surgical Oncology.)
- Published
- 2021
- Full Text
- View/download PDF
4. The prognostic importance of changing serum M30 and M65 values after chemotherapy in patients with advanced-stage non-small-cell lung cancer.
- Author
-
Ustaalioglu BB, Bilici A, Ercan S, Seker M, Orcun A, and Gumus M
- Subjects
- Adult, Aged, Antineoplastic Agents therapeutic use, Biomarkers, Tumor biosynthesis, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung pathology, Disease Progression, Disease-Free Survival, Female, Follow-Up Studies, Humans, Keratin-18 biosynthesis, Lung Neoplasms drug therapy, Lung Neoplasms pathology, Male, Middle Aged, Peptide Fragments biosynthesis, Prognosis, Survival Rate trends, Treatment Outcome, Biomarkers, Tumor blood, Carcinoma, Non-Small-Cell Lung blood, Keratin-18 blood, Lung Neoplasms blood, Peptide Fragments blood
- Abstract
Although oncological treatments are improving, the prognosis of non-small-cell lung cancer (NSCLC) patients has not. Several biomarkers related to prognosis have been evaluated, and M30 and M65 have been reported to be higher in patients with NSCLC than in healthy people. In the current study, we evaluated the clinical importance of the change in serum M30 and M65 values after chemotherapy in patients with NSCLC. Serum M30 and M65 values were measured before and 48 h after chemotherapy in thirty-two patients with advanced NSCLC. The importance of the change in the levels of these markers after chemotherapy was analyzed by univariate analysis. The median serum M65 and M30 values increased significantly after chemotherapy (p < 0.001). The median M30 value after chemotherapy was an important prognostic factor for both overall survival (OS) (p = 0.002) and progression-free survival (PFS) (p = 0.002). Stage and histopathological type were significant both for PFS and OS. Multivariate analysis showed that the median M30 value after chemotherapy was the only independent prognostic factor for PFS (p = 0.04, HR 5.4) and OS (p = 0.02, HR 11.49). Our results indicated that both serum M30 and M65 values increased after chemotherapy in patients with advanced NSCLC, and an elevated serum M30 value was an independent prognostic factor for both PFS and OS.
- Published
- 2013
- Full Text
- View/download PDF
5. Role of human papillomavirus in the development of urothelial carcinoma.
- Author
-
Yavuzer D, Karadayi N, Salepci T, Baloglu H, Bilici A, and Sakirahmet D
- Subjects
- Adult, Aged, Aged, 80 and over, Carcinoma, Transitional Cell pathology, DNA, Viral isolation & purification, Female, Humans, Male, Middle Aged, Neoplasm Staging, Papillomavirus Infections complications, Polymerase Chain Reaction, Urinary Bladder Neoplasms pathology, Young Adult, Carcinoma, Transitional Cell virology, Papillomavirus Infections epidemiology, Urinary Bladder Neoplasms virology
- Abstract
It has been estimated that almost 10% of the worldwide cancer burden is linked to human papillomavirus (HPV) infection. Although the association between HPV and bladder carcinoma has been extensively investigated, data on the role of HPV in bladder carcinogenesis are controversial. The aim of the study was to assess the possible role of human papillomavirus in the development of urothelial bladder carcinomas. Formalin-fixed and paraffin-embedded archival tissue samples were used for DNA extraction. Seventy urothelial bladder carcinoma tissues were screened by nested-polymerase chain reaction (PCR) for HPV DNA with a control group of total 18 cervical tissues with invasive cervical carcinoma and cervical intraepithelial neoplasia III (CIN III). In the study group, we did not find HPV DNA positivity in any of the urothelial carcinomas. In the control group, 15 out of 18 (83.3%) samples were positive for the HPV DNA. These results indicated that there was no association between HPV infection and urothelial carcinomas.
- Published
- 2011
- Full Text
- View/download PDF
6. The role of PET-CT in the differential diagnosis of thymic mass after treatment of patients with lymphoma.
- Author
-
Ustaalioglu BB, Seker M, Bilici A, Canpolat N, Yıldirim E, Kefeli U, Ustaalioglu R, Yilmaz BE, Salepci T, Ozdemir N, and Gumus M
- Subjects
- Adolescent, Adult, Diagnosis, Differential, Female, Humans, Male, Middle Aged, Remission Induction, Retrospective Studies, Young Adult, Fluorodeoxyglucose F18, Hodgkin Disease diagnosis, Lymphoma, Non-Hodgkin diagnosis, Mediastinal Neoplasms diagnosis, Positron-Emission Tomography, Radiopharmaceuticals, Tomography, X-Ray Computed
- Abstract
Thymic hyperplasia is a common phenomenon in both children and young adults after chemotherapy and may explain the finding of a mediastinal mass in patients with malignant lymphoma after complete remission. In the present study, we report 5 cases with malignant lymphoma presenting with a mediastinal mass on CT scan after completion of chemotherapy diagnosed as thymic hyperplasia by PET-CT imaging. We retrospectively analyzed 5 patients who presented with anterior mediastinal masses a median of 4 months (range 3-6) after achieving complete remission following successful treatment for malignant lymphoma. Three patients were diagnosed with Hodgkin's lymphoma (HL) and the others with non-Hodgkin's lymphoma (NHL). The median age of the patients was 23 (range of 18-47). PET-CT was performed on these patients to determine the characteristics of a mass which had been detected on CT. PET-CT was performed for all patients, and the thymic masses demonstrated only mild FDG uptake considered to be consistent with thymic hyperplasia. During a median of 24 months of follow-up, all patients were recurrence-free with a median survival of 15 months (range 10-26 months). It is important to be aware of the possibility of thymic hyperplasia after chemotherapy to avoid misdiagnosis or over-staging of disease, as well as unnecessary biopsies, especially when the presenting anterior mediastinal mass was originally located near the thymus on CT scan. Mild FDG PET uptake was sufficient for the diagnosis of benign disease in the cases in this study.
- Published
- 2011
- Full Text
- View/download PDF
7. The effect of peripheral blood values on prognosis of patients with locally advanced gastric cancer before treatment.
- Author
-
Aliustaoglu M, Bilici A, Ustaalioglu BB, Konya V, Gucun M, Seker M, and Gumus M
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Humans, Lymphocyte Count, Male, Middle Aged, Neutrophils, Platelet Count, Prognosis, Stomach Neoplasms therapy, Survival Rate, Stomach Neoplasms blood, Stomach Neoplasms mortality
- Abstract
We aimed to investigate the prognostic significance of neutrophil, lymphocyte, platelet, mean platelet value (MPV), platelet-lymphocyte ratio (PLR) and neutrophil-lymphocyte ratio (NLR) in patients with locally advanced gastric cancer (LAGC). One hundred sixty-eight patients with LAGC who had been followed-up between 2004 and 2008 were included in present study. The results of hematological (platelet, lymphocyte, neutrophil and MPV) and biochemical (uric acid and LDH) parameters were evaluated before treatment. NLR was divided into two groups as <2.56 and ≥2.57 and PLR was also divided into two groups as ≤160 and >160. Platelet counts and lymphocyte counts were also divided into two groups; ≤300.000/mm3 and >300.000/mm3, and <1,500/mm3 and ≥1,500/mm3, respectively. Results were evaluated with Kaplan-Meier and Long-rank tests. The mean age of patients at diagnosis was 60.1±12.1 and 114 of patients (67.8%) were male. For 168 patients, 48 months overall survival (OS) rate was 45.2% and the median OS was 39 months (range 33-44). In patients whose PLR was less than 160 (n=54), the median OS was 45 months (range 38-52) and also for cases whose PRL was greater than 160 (n=114), the median OS was 27 months (range 22-32) (p=0.006). While for fifty patients whose lymphocyte counts were less than 1,500, the median OS was 27 months (range 21-33), in cases with high lymphocyte counts (≥1,500) (n=118), it was 41 months (range 35-48) (p=0.03). The median OS was 41 (range 34-48) and 30 (range 23-37) months in two platelets groups, respectively (p=0.24). However, in the patients whose NLR was less than 2.56 (n=107), median OS was better than with cases whose NLR was greater than or equal to 2.56 (42 vs. 27 months). Routine peripheral blood counts may be useful prognostic factor for evaluating the accuracy of risk stratification in patients with radically resected gastric cancer Our results need to be confirmed by study including larger sample size in future.
- Published
- 2010
- Full Text
- View/download PDF
8. The association of serum adiponectin levels with histopathological variables in gastric cancer patients.
- Author
-
Seker M, Bilici A, Sonmez B, Ustaalioğlu BB, Gumus M, Gozu H, Sargin M, Orcun A, Gezen C, Eser M, Bildik N, and Salepci T
- Subjects
- Adult, Aged, Blood Glucose, Body Mass Index, C-Peptide blood, Case-Control Studies, Female, Gastrectomy, Humans, Insulin blood, Insulin Resistance, Lymph Node Excision, Male, Middle Aged, Neoplasm Invasiveness, Neoplasm Staging, Obesity, Prognosis, Risk Factors, Stomach Neoplasms pathology, Stomach Neoplasms surgery, Survival Rate, Adiponectin blood, Gastric Mucosa metabolism, Stomach Neoplasms blood
- Abstract
Adiponectin is a peptide hormone secreted from the adipose tissue, affecting the proliferation and insulin sensitivity in different cell types. The levels of adiponectin have been found to be decreased in hyperinsulinemia and insulin resistant states, such as obesity. The previous studies have suggested that plasma adiponectin levels are decreased in patients with endometrial and breast cancer. In our study, the relationship among serum adiponectin levels, demographic features and histopathological variables was evaluated in gastric cancer patients. Forty consecutive patients with gastric cancer who underwent gastrectomy with standard lymph node dissection were included and 43 healthy controls were included in this study. The serum levels of glucose, insulin, C-peptide, HbA1c and adiponectin were measured in both groups. We analyzed the correlation among these parameters and patients' demographic features, such as age, gender, body mass index (BMI) and histopathological variables such as tumor localization, stage, nodal status, histological grade, vascular and lymphatic invasion. The mean age was 60.05+9.72 in patients, while it was 38.6+12.73 in controls. The mean serum adiponectin levels were 12.62+7.9 and 10.07+6.72 ng/ml, respectively, in groups. There was no different in terms of adiponectin, C-peptide, HOMA-R level in both groups. On the other hand, BMI, glucose and insulin levels were significantly different in gastric cancer patients in comparison with the controls. There was no correlation among the levels of adiponectin, BMI, insulin and c-peptide levels in patient group (P>0.05). The adiponectin levels of woman were significantly lower than male patients (P=0.002). No relations were detected among tumor stage, tumor localization, nodal status, lymphatic and vascular invasion, and the levels of serum adiponectin (P>0.05). Interestingly, a positive correlation was found between tumor grade and plasma adiponectin levels (r=0.372; P=0.018). Our results suggest that plasma adiponectin levels were similar in both patients with gastric cancer and the controls. In addition, no correlation was found between adiponectin levels and demographic features and histopathological variables of patients. But, in undifferentiated tumors, plasma adiponectin level was significantly higher than well-differentiated grade tumors.
- Published
- 2010
- Full Text
- View/download PDF
9. Determining of metastatic lymph node ratio in patients who underwent D2 dissection for gastric cancer.
- Author
-
Bilici A, Seker M, Ustaalioglu BB, Yilmaz B, Doventas A, Salepci T, and Gumus M
- Subjects
- Adult, Aged, Algorithms, Carcinoma blood supply, Carcinoma mortality, Carcinoma pathology, Disease-Free Survival, Female, Follow-Up Studies, Gastrectomy methods, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Multivariate Analysis, Neoplasm Invasiveness, Neoplasm Staging, Prognosis, Proportional Hazards Models, Retrospective Studies, Stomach Neoplasms blood supply, Stomach Neoplasms mortality, Stomach Neoplasms pathology, Tumor Burden, Carcinoma surgery, Lymph Node Excision, Lymph Nodes pathology, Lymphatic Metastasis, Stomach Neoplasms surgery
- Abstract
The purpose of this study was to determine outcome of the ratio of metastatic lymph nodes to the total number of dissected lymph nodes (MLR) in patients with gastric cancer. We retrospectively analyzed 111 patients who underwent D(2) lymph node dissection. The prognostic factors including UICC/AJCC TNM classification and MLR were evaluated by univariate and multivariate analysis. The MLR was significantly higher in patients with a larger tumor, lymphatic vessel invasion, blood vessel invasion and perineural invasion, and advanced stage. Moreover, the MLR was significantly associated with the depth of invasion and the number of lymph node metastasis. The univariate analysis revealed for overall survival (OS) that stage of disease, lymphatic vessel invasion, blood vessel invasion, perineural invasion, lymph node metastasis (UICC/AJCC pN stage) and MLR were relevant prognostic indicators. Furthermore, both UICC/AJCC pN stage and MLR were detected as prognostic factor by multivariate analysis, as was perineural invasion. Our results indicated that MLR and UICC/AJCC pN staging system were important prognostic factors for OS of patients with D(2) lymph node dissection in gastric cancer in a multivariate analysis. MLR may be useful for evaluating the status of lymph node metastasis in gastric cancer.
- Published
- 2010
- Full Text
- View/download PDF
10. Prognostic significance of perineural invasion in patients with gastric cancer who underwent curative resection.
- Author
-
Bilici A, Seker M, Ustaalioglu BB, Kefeli U, Yildirim E, Yavuzer D, Aydin FM, Salepci T, Oncel M, and Gumus M
- Subjects
- Adult, Aged, Aged, 80 and over, Analysis of Variance, Female, Humans, Lymphatic Metastasis, Male, Middle Aged, Neoplasm Invasiveness, Peripheral Nerves surgery, Prognosis, Retrospective Studies, Stomach Neoplasms mortality, Stomach Neoplasms pathology, Survival Rate, Gastrectomy, Peripheral Nerves pathology, Stomach Neoplasms surgery
- Abstract
Background: The prognostic significance of perineural invasion (PNI) in gastric cancer has been previously investigated in a few studies, but had not reached a consensus. The aim of this study was to determine the prognostic value of PNI in patients with gastric cancer who underwent curative resection., Materials and Methods: We retrospectively analyzed 238 patients who had undergone curative gastrectomy. Paraffin sections of surgical specimens from all patients were stained with hematoxylin and eosin. PNI was defined when carcinoma cells infiltrated into the perineurium or neural fascicles. PNI and the other prognostic factors were evaluated by univariate and multivariate analysis., Results: PNI was detected as positive in 180 of the 238 patients (75.6%). pT stage, tumor size, lymph node metastasis, clinical stage, tumor differentiation, Borrmann classification, histological type, lymphatic vessel invasion, and blood vessel invasion were closely associated with the presence of PNI. The PNI-positive tumors had significantly larger size and more lymph node metastasis than the PNI-negative tumors (P = .001 and P < .001, respectively). The median survival of the PNI-positive patients was significantly worse than that of the PNI-negative patients (28.1 vs. 64.9 months, P = .001). Multivariate analysis indicated that the positivity of PNI was an independent prognostic factor (P = .02, hazard ratio [HR]: 2.75; 95% confidence interval [95% CI]:1.12-3.13) as were classical clinicopathological features., Conclusion: Our results showed that the frequency of PNI was high in patients with gastric cancer who underwent curative gastrectomy and the proportion of PNI positivity increased with progression and clinical stage of disease. PNI may be useful in detecting patients who had poor prognosis after curative resection in gastric cancer.
- Published
- 2010
- Full Text
- View/download PDF
11. Neoadjuvant chemotherapy for locally advanced breast cancer: a single center experience.
- Author
-
Ustaalioglu BB, Gumus M, Bilici A, Seker M, Dane F, Salepci T, Salman T, Aliustaoglu M, Eser M, Gezen C, Yaylaci M, and Turhal NS
- Subjects
- Adult, Aged, Aged, 80 and over, Breast Neoplasms mortality, Female, Follow-Up Studies, Humans, Middle Aged, Retrospective Studies, Survival Rate trends, Breast Neoplasms drug therapy, Breast Neoplasms pathology, Chemotherapy, Adjuvant, Neoadjuvant Therapy
- Abstract
Neoadjuvant chemotherapy (NAC) is one of the treatment options for patients with locally advanced breast cancer (LABC). Preoperative chemotherapy potentially may reduce the extent of the surgery and offers the opportunity to assess the chemosensitivity of the tumor in vivo. Herein, we evaluated the results of NAC in Turkish LABC patients. We retrospectively analyzed 73 LABC patients. Anthracycline/taxane-based chemotherapy regimens were administered. Patients were stratified according to age, menopausal status, type of surgery, response to the treatment, histopathological properties, and survival. After 3-6 cycles of chemotherapy, patients were re-staged radiologically and surgery was performed in operable patients. Adjuvant chemotherapy was administered as needed. The median age was 45 (29-93) at the time of diagnosis. Sixteen percentage of patients were younger than 35 years of age and 45.2% were premenopausal. Median follow-up time was 20.2 months. Sixty-seven out of 73 patients responded to therapy (89%). Breast conserving surgery was possible in the 15% of the patients. In histopathological analysis, lymph node invasion was detected in 85%. The estrogen (ER) and progesterone (PR) receptor were positive in 78.1% and c-erb-B2 was positive in 17.5% of patients. The median disease-free survival (DFS) was 44 months (SE: 9; %95 CI: 27.1-60.8), overall survival (OS) was not reached at the time of analysis. Three-year DFS and OS were 58% and 91.9%, respectively. In a multivariate Cox regression analyses; no demographic or pathologic prognostic parameter predicted overall survival. In recent years, NAC in breast cancer has become a viable treatment option for patients with LABC. NAC is not commonly applied in Turkey. The response rate to NAC in Turkish breast cancer patients is encouragingly high. Broader efforts should be made to evaluate breast cancer patients preoperatively at tumor boards for proper treatment sequence.
- Published
- 2010
- Full Text
- View/download PDF
12. Preoperative serum leptin levels in patients with breast cancer.
- Author
-
Aliustaoglu M, Bilici A, Gumus M, Colak AT, Baloglu G, Irmak R, Seker M, Ustaalioglu BB, Salman T, Sonmez B, Salepci T, and Yaylaci M
- Subjects
- Adolescent, Adult, Aged, Body Mass Index, Breast Neoplasms pathology, Female, Humans, Middle Aged, Postmenopause blood, Premenopause blood, Risk Factors, Young Adult, Biomarkers, Tumor blood, Breast Neoplasms blood, Breast Neoplasms surgery, Leptin blood, Preoperative Care methods
- Abstract
Leptin is an adipocyte-derived protein and plays an important role in the control of body weight by acting as a neurohormone regulating energy balance and food intake in the hypothalamus. The high serum leptin levels and the overexpression of leptin receptors have been documented in breast cancer patients, but the levels never checked preoperatively. In the present study, the relationship between preoperative serum leptin levels of the breast cancer patients and the healthy controls were evaluated. The serum leptin levels in 30 breast cancer patients were compared to 30 healthy female volunteers. In addition, the association of serum leptin levels and the various well-known risk factors were studied. Serum leptin levels of patients with breast cancer (28.55 + 19.7 ng/ml) were tended to be higher than those of controls (26.43 + 19.4 ng/ml), but it did not reach statistical difference (P = 0.712). There was significant correlation between the expression of ER, PR, and serum leptin levels (P = 0.018 and 0.037, respectively), but not with the HER-2/neu receptor expression (P = 0.067). Also association was not found between the tumor size, lymph node involvement, and the levels of serum leptin (P = 0.235, 0.34, and 0.86, respectively). The serum leptin level was also found to be similar in premenopausal (24.85 +/- 18.14 ng/ml) and postmenopausal (30.49 +/- 17.19 ng/ml) patients (P = 0.235). The preoperative serum leptin levels in breast cancer patients were similar to healthy controls. In subset analysis, the significant correlation between the leptin level and hormonal status was noted, but association with HER-2/neu was not detected. These findings should be confirmed with larger studies.
- Published
- 2010
- Full Text
- View/download PDF
13. 5-Fluorouracil induces arterial vasoconstrictions but does not increase angiotensin II levels.
- Author
-
Salepci T, Seker M, Uyarel H, Gumus M, Bilici A, Ustaalioğlu BB, Oztürk A, Sonmez B, Orcun A, Ozates M, Irmak R, and Yaylaci M
- Subjects
- Adult, Aged, Angiotensin II biosynthesis, Brachial Artery physiology, Cardiovascular Diseases blood, Cardiovascular Diseases chemically induced, Colonic Neoplasms blood, Colonic Neoplasms drug therapy, Female, Fluorouracil adverse effects, Fluorouracil therapeutic use, Humans, Male, Middle Aged, Stomach Neoplasms blood, Stomach Neoplasms drug therapy, Up-Regulation drug effects, Vasoconstriction physiology, Angiotensin II blood, Brachial Artery drug effects, Fluorouracil pharmacology, Vasoconstriction drug effects
- Abstract
Because the mechanisms of 5-Fluorouracil (5-FU) cardiotoxicity have not yet been completely identified, prophylactic options are not available. To our knowledge, there are no published data investigating the use of angiotensin converting enzyme (ACE) inhibitors for 5-Fluorouracil-associated cardiotoxicity. In this study, we aimed to evaluate the influence of 5-FU administration on the diameter of the brachial artery and the levels of angiotensin II. The patients were administered bolus 5-FU/leucovorin in the study group. Angiotensin II and troponin T assays, complete blood cell counts, hepatic and renal function tests were analyzed in five consecutive blood samples in the initiation, just after termination, and on 24, 48, and 72 h after termination of the regimen. Pre- and post-treatment angiotensin II and troponin T assays, complete blood cell counts, hepatic and renal function tests were also analyzed in the control group. Brachial arterial diameters were measured and recorded in all patients before and after the treatment. A total of 59 patients were included in this study. Thirty one out of 59 patients (52.5%) were in the 5-FU study group and the remaining 28 patients (47.5%) were in the control group. Basal and post-treatment brachial artery diameters in the 5-FU study group were 0.436 +/- 0.51 and 0.423 +/- 0.50 cm, respectively (P = 0.001). The corresponding values in the controls were 0.3954 +/- 0.50 and 0.3957 +/- 0.49 cm, basal and post-treatment, respectively (P = 0.979). Angiotensin II levels were not changed significantly at serial measurements (P = 0.496). Moreover, the corresponding measurements were not statistically different in both two groups treated with and without 5-FU (P = 0.372). The pathophysiology of 5-FU-induced cardiac toxicity has not yet been elucidated. In the present study, 5-FU-associated vasoconstriction was not dependent on angiotensin II levels, thus we suggest that the prophylactic administration of ACE inhibitors cannot prevent cardiotoxicity in these patients. The underlying mechanisms of cardiotoxicity related to 5-FU might be multifactorial; nevertheless, further prospective investigation for the toxic effects of fluoropyrimidines on the coronary endothelium and myocardium are needed.
- Published
- 2010
- Full Text
- View/download PDF
14. Tissue levels of adiponectin in breast cancer patients.
- Author
-
Karaduman M, Bilici A, Ozet A, Sengul A, Musabak U, and Alomeroglu M
- Subjects
- Adult, Aged, Breast Neoplasms diagnosis, Breast Neoplasms pathology, Case-Control Studies, Female, Humans, Incidence, Middle Aged, Neoplasm Staging, Receptor, ErbB-2, Adiponectin analysis, Breast Neoplasms epidemiology
- Abstract
Background: Adiponectin is a new adipocyte-secreted protein and associated with insulin-resistant status, such as type 2 diabetes mellitus and obesity. The inverse correlation between serum adiponectin levels and breast cancer risk was recently documented. On the other hand, the association of tissue adiponectin levels with breast cancer has not been previously reported. Thus, in the present study, the relationship between tissue adiponectin levels and breast cancer was evaluated., Methods: We analyzed the correlation between tissue adiponectin levels and the occurrence of breast cancer in a case-control study comprising 27 women with diagnosed and histologically confirmed breast cancer and 33 women with fibroadenoma. In addition, the association of tissue adiponectin levels with the various classical risk factors, such as body mass index, menopausal status and, tumor size, stage, lymph node status, hormonal status were also studied., Results: Tissue adiponectin levels in patients with breast cancer (0.75 +/- 0.06) were significantly higher than those in controls (0.68 +/- 0.1) (P = 0.02). The high tissue adiponectin levels were associated with significantly (P = 0.001) an increased risk for breast cancer compared with those in the low tissue adiponectin levels (OR, 1.34; 95% CI, 1.12-1.84) in breast cancer patients. In addition, postmenopausal women with the high tissue adiponectin levels showed a significantly (P = 0.003) an increased risk for breast cancer compared with women in low tissue adiponectin levels (OR, 1.63; 95% CI, 1.23-1.90). The correlation between BMI and breast cancer was not found (P > 0.05). Furthermore, the status of estrogen receptor, progesterone receptor, HER-2/neu receptor and lymph nodes involvement were established, no effect on the tissue adiponectin levels in patients with breast cancer and no correlations were detected among tumor stage, tumor size and the levels of tissue adiponectin (P > 0.05)., Conclusion: Our results suggest that the high tissue adiponectin levels significantly detected in breast cancer patients and associated with an increased risk for breast cancer.
- Published
- 2007
- Full Text
- View/download PDF
15. A case-control study of non-alcoholic fatty liver disease in breast cancer.
- Author
-
Bilici A, Ozguroglu M, Mihmanli I, Turna H, and Adaletli I
- Subjects
- Adult, Aged, Aged, 80 and over, Alanine Transaminase blood, Alkaline Phosphatase blood, Aspartate Aminotransferases blood, Case-Control Studies, Fatty Liver diagnostic imaging, Female, Humans, L-Lactate Dehydrogenase blood, Middle Aged, Risk Factors, Ultrasonography, gamma-Glutamyltransferase blood, Breast Neoplasms complications, Fatty Liver epidemiology
- Abstract
Background: Patients with breast cancer sometimes present with increased liver enzymes during follow-up period that may be consistent with hepatic steatosis. This effect known as non-alcoholic fatty liver disease may be associated with the malignancy itself, drugs or some other well-known risk factors that may induce steatosis. We studied the influences of primary disease and treatment on steatosis in patients with breast cancer., Materials and Methods: There were four groups of patients in our study. Group 1: 40 newly diagnosed, previously untreated breast cancer; Group 2: 45 cases of breast cancer treated with systemic therapy; Group 3: 40 cases of ovarian cancer; Group 4: 40 healthy women. Hepatic steatosis was evaluated by sonography by two radiologist, independently. We also evaluated major risk factors, biochemical findings, and influences of treatment on hepatic steatosis., Results: We detected steatosis in 63%, 72%, 77%, and 48% of patients in groups 1, 2, 3, and 4, respectively. There was a statistically significant difference only between groups 3 and 4 (P = 0.045). However, grade 2 and 3 steatosis were more frequent in breast cancer patients (group 1 and 2), compared with mild steatosis in ovarian cancer patients and healthy women. Although a good correlation was found between tamoxifen use and chemotherapy on development of non-alcoholic fatty liver disease, no association of hepatic steatosis with transaminase levels was found, which might be of help for earlier detection of steatosis. AST/ALT ratio was found to have no impact on the rate of hepatic steatosis, contrary to the literature., Conclusion: Hepatic steatosis, excluding patients with grade 1 steatosis, which may be a normal variant, were more readily detected in patients with breast cancer. This effect was aggravated by use of tamoxifen, but not the chemotherapy. Non-alcoholic fatty liver disease in patients with breast cancer may be associated with the primary tumor itself or some well-known risk factors such as obesity, hyperlipidemia, and diabetes mellitus, which needs to be explored.
- Published
- 2007
- Full Text
- View/download PDF
16. Flutamide-induced acute renal failure in a patient with metastatic prostate cancer.
- Author
-
Altiparmak MR, Bilici A, Kisacik B, and Ozguroglu M
- Subjects
- Acute Kidney Injury blood, Androgen Antagonists therapeutic use, Flutamide therapeutic use, Humans, Male, Middle Aged, Prostatic Neoplasms secondary, Acute Kidney Injury chemically induced, Androgen Antagonists adverse effects, Flutamide adverse effects, Prostatic Neoplasms drug therapy
- Abstract
Androgen blockage, with either orchiectomy or luteinizing hormone releasing hormone (LHRH) analogs combined with an antiandrogen drug, is the standard treatment for metastatic prostate cancer. Flutamide is a non-steroidal antiandrogen drug that is frequently used for total androgen blockage. We report on a 54-yr-old man with metastatic prostate cancer who developed nonoliguric acute renal failure (ARF) during treatment with flutamide. Following discontinuation of flutamide therapy, his renal functions returned to normal limits within 4 wk. After a rechallenge with flutamide, serum levels of BUN and creatinine increased again. His renal function recovered completely after the cessation of the drug for the second time. This observation confirm that ARF may be clearly attributed to flutamide therapy. Although very rare, flutamide-induced ARF should be considered.
- Published
- 2002
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.